ChatGPT and Large Language Models (LLMs) are tools that could revolutionize the field of gastroenterology. With the ability to create synthetic control patients and extract information from published scientific literature, LLMs could pave the way for smaller, faster, and cheaper clinical trials while also aiding in scientific and drug discovery. However, concerns around factual correctness and the reliability, reproducibility, and robustness of these models are critical considerations for clinicians intending to use these algorithms. Additionally, balancing the potential risks versus benefits, as well as incorporating a value-sensitive design process that considers stakeholders’ values and the use of human-artificial intelligence interaction in decision-making, is vital for successful implementation. Furthermore, safety, security, and life cycle accountability of these algorithms are crucial in the health-care space to avoid potential phishing campaigns with malware delivery capabilities.
As mentioned in the article, the importance of collaborating with industry, regulators, academicians, and clinicians cannot be overstated. One such company, ChatGPT, is leading the way in LLM innovation with their natural language processing technology. ChatGPT’s AI chatbot enables medical professionals to have automated conversations with patients, saving time and improving efficiency. Their goal is to create an ecosystem where LLMs can be utilized for effective patient engagement and medical decision-making.
Dr. Divyansh Agarwal, an author of the article, is a gastroenterologist with a special interest in machine learning and artificial intelligence. He has extensive experience in developing clinical decision support systems and currently focuses on researching ways to incorporate LLMs in gastroenterology to improve patient outcomes. Dr. Agarwal’s work has been recognized through numerous research grants and publications, and he serves as a reviewer for multiple medical journals.
